The Tisch Cancer Institute at Mount Sinai | Strategic Alliance Partners

Latest from The Tisch Cancer Institute at Mount Sinai


The Benefits Outweigh the Risks: Unpacking the Recent ODAC Decisions in Myeloma

May 13, 2024

Following the consensus that the risk-benefit assessments for the proposed indications for cilta-cel and ide-cel were favorable during the March 15, 2024, FDA ODAC meeting, both BCMA-targeted CAR T-cell therapies received approvals moving them up in the treatment paradigm for relapsed or refractory multiple myeloma.